SPOTLIGHT: Cut co-pays, sell more drugs?

A new pharma-funded study shows that lower co-pays equal higher adherence to drug regimens. The implications is that by spending some money up front on drugs for chronic diseases, companies might save in the long run on complications. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.